person · Reporting owner

KWON YOUNG

Disclosed activity across 2 companies

Tapewire entity: 66864
SEC CIK: 0001733094

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ADMA BIOLOGICS, INC.ADMA · Entity 4477	Director	February 09, 2026	February 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ADMA BIOLOGICS, INC.

Report date February 09, 2026 · Filed February 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	263,020	Reported balance After 2026-02-09 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-02-09 · Grant · Acquired 10,690 · Balance 263,020 F1: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date. F2: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 246,885 shares of common stock owned by the Reporting Person.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.37 · Expires 2036-02-09	Direct	17,730	Reported balance After 2026-02-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-02-09 · Grant · Acquired 17,730 · Balance 17,730 F3: These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.

F2: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 246,885 shares of common stock owned by the Reporting Person.

F3: These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MOMENTA PHARMACEUTICALS INC

Report date October 01, 2020 · Filed October 01, 2020

Section 16 reporting ended · disclosed 2020-10-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-10-01 transaction · row 1 1 source row Row 1 · 2020-10-01 · Disposition to issuer · Disposed 160,633 · Balance 0 F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-10-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-10-01 · Disposition to issuer · Disposed 45,000 · Balance 0 F2: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-10-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-10-01 · Disposition to issuer · Disposed 31,500 · Balance 0 F2: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-10-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-10-01 · Disposition to issuer · Disposed 2,819 · Balance 0 F2: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-10-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-10-01 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.58 · Expires 2023-02-19	Direct	Reported balance After 2020-10-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-10-01 · Disposition to issuer · Disposed 3,572 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.96 · Expires 2024-02-18	Direct	Reported balance After 2020-10-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-10-01 · Disposition to issuer · Disposed 3,466 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.02 · Expires 2025-02-18	Direct	Reported balance After 2020-10-01 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-10-01 · Disposition to issuer · Disposed 6,712 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.56 · Expires 2025-08-11	Direct	Reported balance After 2020-10-01 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-10-01 · Disposition to issuer · Disposed 3,214 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.83 · Expires 2026-02-09	Direct	Reported balance After 2020-10-01 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-10-01 · Disposition to issuer · Disposed 2,363 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.85 · Expires 2027-02-07	Direct	Reported balance After 2020-10-01 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2020-10-01 · Disposition to issuer · Disposed 6,766 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.76 · Expires 2029-02-11	Direct	Reported balance After 2020-10-01 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2020-10-01 · Disposition to issuer · Disposed 19,344 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.87 · Expires 2030-02-07	Direct	Reported balance After 2020-10-01 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2020-10-01 · Disposition to issuer · Disposed 3,137 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.26 · Expires 2021-02-22	Direct	Reported balance After 2020-10-01 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2020-10-01 · Disposition to issuer · Disposed 8,502 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.58 · Expires 2023-02-19	Direct	Reported balance After 2020-10-01 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2020-10-01 · Disposition to issuer · Disposed 7,228 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.96 · Expires 2024-02-18	Direct	Reported balance After 2020-10-01 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2020-10-01 · Disposition to issuer · Disposed 1,356 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.02 · Expires 2025-02-18	Direct	Reported balance After 2020-10-01 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2020-10-01 · Disposition to issuer · Disposed 13,013 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.56 · Expires 2025-08-11	Direct	Reported balance After 2020-10-01 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2020-10-01 · Disposition to issuer · Disposed 6,786 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.83 · Expires 2026-02-09	Direct	Reported balance After 2020-10-01 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2020-10-01 · Disposition to issuer · Disposed 35,437 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.85 · Expires 2027-02-07	Direct	Reported balance After 2020-10-01 transaction · row 20 Instrument identity requires review; Table II rows are not merged. 1 source row Row 20 · 2020-10-01 · Disposition to issuer · Disposed 38,334 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.76 · Expires 2029-02-11	Direct	Reported balance After 2020-10-01 transaction · row 21 Instrument identity requires review; Table II rows are not merged. 1 source row Row 21 · 2020-10-01 · Disposition to issuer · Disposed 115,656 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.87 · Expires 2030-02-07	Direct	Reported balance After 2020-10-01 transaction · row 22 Instrument identity requires review; Table II rows are not merged. 1 source row Row 22 · 2020-10-01 · Disposition to issuer · Disposed 96,863 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.

F2: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price.

F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 07, 2020 Filed May 11, 2020 16:20 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	1,409	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-20-005717 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document
April 20, 2020 Filed Apr 21, 2020 16:20 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	1,614	$28.97	$46,757.58	Disclosure SEC source: 0001179110-20-004999 · edgar.xml · nonDerivative · entry 2 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,722 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
April 17, 2020 Filed Apr 21, 2020 16:20 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionRestricted Stock Units · Derivative	3,500	$0.00	$0.00	Disclosure SEC source: 0001179110-20-004999 · edgar.xml · derivative · entry 3 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 3,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17,2018. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document
April 17, 2020 Filed Apr 21, 2020 16:20 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	3,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-20-004999 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17,2018. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document
March 06, 2020 Filed Mar 9, 2020 17:17 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	7,356	$28.96	$213,029.76	Disclosure SEC source: 0001179110-20-003316 · edgar.xml · nonDerivative · entry 2 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,836 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan Read SEC document
March 05, 2020 Filed Mar 9, 2020 17:17 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	GrantRestricted Stock Units · Derivative	15,000	$0.00	$0.00	Disclosure SEC source: 0001179110-20-003316 · edgar.xml · derivative · entry 3 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of MNTA Common Stock. F5 · derivative.exercise_date: Subject to the officer's continued employment with the company, the Restricted Stock Units will vest on March 5, 2021. F5 · derivative.expiration_date: Subject to the officer's continued employment with the company, the Restricted Stock Units will vest on March 5, 2021. Read SEC document
March 05, 2020 Filed Mar 9, 2020 17:17 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	GrantCommon Stock	15,000	$0.00	$0.00	Disclosure SEC source: 0001179110-20-003316 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,192 F1 · kind: Shares received pursuant to settlement of Performance Stock Units that were granted on October 17, 2018. F2 · balance_after: Includes 1,089 shares acquired under the issuer's employee stock purchase plan at a price of $9.76 per share on January 31, 2020. Read SEC document
February 13, 2020 Filed Feb 14, 2020 18:54 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	9,016	$30.03	$270,750.48	Disclosure SEC source: 0001179110-20-001670 · edgar.xml · nonDerivative · entry 2 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,103 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
February 12, 2020 Filed Feb 14, 2020 18:54 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionRestricted Stock Units · Derivative	27,500	$0.00	$0.00	Disclosure SEC source: 0001179110-20-001670 · edgar.xml · derivative · entry 3 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 12, 2018. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date. Read SEC document
February 12, 2020 Filed Feb 14, 2020 18:54 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	27,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-20-001670 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 12, 2018. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document
February 11, 2020 Filed Feb 12, 2020 17:27 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	350	$32.23	$11,280.50	Disclosure SEC source: 0001179110-20-001522 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,619 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
February 10, 2020 Filed Feb 11, 2020 19:02 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	408	$31.50	$12,852.00	Disclosure SEC source: 0001179110-20-001468 · edgar.xml · nonDerivative · entry 2 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,969 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
February 07, 2020 Filed Feb 11, 2020 19:02 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	GrantStock Option (Right to Buy) · Derivative	100,000	$0.00 Strike: $31.87	$0.00	Disclosure SEC source: 0001179110-20-001468 · edgar.xml · derivative · entry 5 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-07 F5 · shares: Represents options granted by the issuer pursuant to the issuer's 2013 Incentive Award Plan, as amended and restated. F6 · derivative.exercise_date: Subject to certain criteria, the stock option will vest and become exercisable with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document
February 07, 2020 Filed Feb 11, 2020 19:02 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	GrantRestricted Stock Units · Derivative	50,000	$0.00	$0.00	Disclosure SEC source: 0001179110-20-001468 · edgar.xml · derivative · entry 4 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F8 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of MMTA common stock. F7 · shares: Represents restricted stock units granted by the issuer pursuant to the issuer's 2013 Incentive Award Plan, as amended and restated. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document
February 07, 2020 Filed Feb 11, 2020 19:02 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionRestricted Stock Units · Derivative	1,409	$0.00	$0.00	Disclosure SEC source: 0001179110-20-001468 · edgar.xml · derivative · entry 3 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,638 Underlying: Common Stock · 1,409 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document
February 07, 2020 Filed Feb 11, 2020 19:02 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	1,409	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-20-001468 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document
January 21, 2020 Filed Jan 22, 2020 17:13 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	1,235	$30.08	$37,148.80	Disclosure SEC source: 0001179110-20-000699 · edgar.xml · nonDerivative · entry 2 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,968 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
January 17, 2020 Filed Jan 22, 2020 17:13 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionRestricted Stock Units · Derivative	3,500	$0.00	$0.00	Disclosure SEC source: 0001179110-20-000699 · edgar.xml · derivative · entry 3 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,500 Underlying: Common Stock · 3,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17,2018. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document
January 17, 2020 Filed Jan 22, 2020 17:13 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	3,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-20-000699 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17,2018. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document
November 12, 2019 Filed Nov 13, 2019 17:12 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	529	$16.18	$8,559.22	Disclosure SEC source: 0001179110-19-011659 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,703 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
November 08, 2019 Filed Nov 12, 2019 16:21 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	632	$16.06	$10,149.92	Disclosure SEC source: 0001179110-19-011615 · edgar.xml · nonDerivative · entry 2 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,232 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
November 07, 2019 Filed Nov 12, 2019 16:21 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionRestricted Stock Units · Derivative	1,410	$0.00	$0.00	Disclosure SEC source: 0001179110-19-011615 · edgar.xml · derivative · entry 3 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,047 Underlying: Common Stock · 1,410 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document
November 07, 2019 Filed Nov 12, 2019 16:21 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	1,410	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-19-011615 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document
October 18, 2019 Filed Oct 21, 2019 16:20 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	6,365	$13.83	$88,027.95	Disclosure SEC source: 0001179110-19-011134 · edgar.xml · nonDerivative · entry 2 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,454 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
October 17, 2019 Filed Oct 21, 2019 16:20 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionRestricted Stock Units · Derivative	14,000	$0.00	$0.00	Disclosure SEC source: 0001179110-19-011134 · edgar.xml · derivative · entry 3 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 14,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17,2018. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document
October 17, 2019 Filed Oct 21, 2019 16:20 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	14,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-19-011134 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17,2018. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document
August 12, 2019 Filed Aug 13, 2019 17:03 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	533	$11.64	$6,204.12	Disclosure SEC source: 0001179110-19-009459 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,819 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
August 08, 2019 Filed Aug 9, 2019 16:20 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	626	$11.82	$7,399.32	Disclosure SEC source: 0001179110-19-009338 · edgar.xml · nonDerivative · entry 2 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,362 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
August 08, 2019 Filed Aug 13, 2019 16:47 UTC Amendment	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	636	$11.67	$7,422.12	Disclosure SEC source: 0001179110-19-009447 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,352 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · shares: The original Form 4 filed on August 9, 2019 is amended by this Form 4/A to correctly reflect the reporting person's share disposal of 636, not 626 shares of common stock. F3 · price: The original Form 4 filed on August 9, 2019 is amended by this Form 4/A to correctly reflect the reporting person's selling price of $11.67 per share, not $11.82 per share. F4 · balance_after: The original Form 4 filed on August 9, 2019 is amended by this Form 4/A to correctly reflect the reporting person's ownership balance of 101,352, not 101,362 shares of common stock. Read SEC document
August 07, 2019 Filed Aug 9, 2019 16:20 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionRestricted Stock Units · Derivative	1,409	$0.00	$0.00	Disclosure SEC source: 0001179110-19-009338 · edgar.xml · derivative · entry 3 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,457 Underlying: Common Stock · 1,409 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017. F5 · derivative.exercise_date: Subject to certain criteria, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F5 · derivative.expiration_date: Subject to certain criteria, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document
August 07, 2019 Filed Aug 9, 2019 16:20 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	1,409	$0.00	$0.00	Disclosure SEC source: 0001179110-19-009338 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017. F2 · balance_after: Includes 1061 shares acquired under the issuer's employee stock purchase plan at a price of $9.61 per share on July 31, 2019. Read SEC document
May 10, 2019 Filed May 14, 2019 18:56 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionStock Option (Right to Buy) · Derivative	2,998	$0.00 Strike: $13.26	$0.00	Disclosure SEC source: 0001179110-19-006034 · edgar.xml · derivative · entry 3 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,998 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 10, 2019 Filed May 14, 2019 18:56 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	2,998	$13.26	$39,753.48	Disclosure SEC source: 0001179110-19-006034 · edgar.xml · nonDerivative · entry 2 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 10, 2019 Filed May 14, 2019 18:56 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	354	$14.00	$4,956.00	Disclosure SEC source: 0001179110-19-006034 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,520 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
May 08, 2019 Filed May 9, 2019 16:25 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	419	$13.68	$5,731.92	Disclosure SEC source: 0001179110-19-005768 · edgar.xml · nonDerivative · entry 2 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,874 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
May 07, 2019 Filed May 9, 2019 16:25 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionRestricted Stock Units · Derivative	1,410	$0.00	$0.00	Disclosure SEC source: 0001179110-19-005768 · edgar.xml · derivative · entry 3 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,866 Underlying: Common Stock · 1,410 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017. F4 · derivative.exercise_date: Subject to certain criteria, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F4 · derivative.expiration_date: Subject to certain criteria, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document
May 07, 2019 Filed May 9, 2019 16:25 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	1,410	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-19-005768 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document
April 13, 2019 Filed Apr 16, 2019 17:04 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Disposition to issuerCommon Stock	30,000	$0.00	$0.00	Disclosure SEC source: 0001179110-19-004993 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,883 Read SEC document
February 20, 2019 Filed Feb 22, 2019 16:03 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	351	$14.05	$4,931.55	Disclosure SEC source: 0001179110-19-002310 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,883 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
February 14, 2019 Filed Feb 19, 2019 16:53 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	4,450	$13.10	$58,295.00	Disclosure SEC source: 0001179110-19-002089 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,234 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
February 13, 2019 Filed Feb 14, 2019 16:27 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	8,358	$12.70	$106,146.60	Disclosure SEC source: 0001179110-19-001907 · edgar.xml · nonDerivative · entry 2 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,684 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
February 12, 2019 Filed Feb 13, 2019 16:43 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	414	$12.77	$5,286.78	Disclosure SEC source: 0001179110-19-001834 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,542 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
February 12, 2019 Filed Feb 14, 2019 16:27 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionRestricted Stock Units · Derivative	27,500	$0.00	$0.00	Disclosure SEC source: 0001179110-19-001907 · edgar.xml · derivative · entry 3 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 12, 2018. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date. Read SEC document
February 12, 2019 Filed Feb 14, 2019 16:27 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	27,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-19-001907 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 12, 2018. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document
February 11, 2019 Filed Feb 13, 2019 16:43 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	GrantStock Option (Right to Buy) · Derivative	135,000	$0.00 Strike: $12.76	$0.00	Disclosure SEC source: 0001179110-19-001834 · edgar.xml · derivative · entry 2 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2029-02-11 F2 · shares: Represents options granted by the issuer pursuant to the issuer's 2013 Incentive Award Plan, as amended and restated. F3 · derivative.exercise_date: The stock option will vest and become exercisable with respect to 33,750 shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. All vesting is subject to Young Kwon's continued service to the Company through the applicable vesting date. Read SEC document
February 08, 2019 Filed Feb 11, 2019 16:24 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	494	$11.52	$5,690.88	Disclosure SEC source: 0001179110-19-001700 · edgar.xml · nonDerivative · entry 2 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,956 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
February 07, 2019 Filed Feb 11, 2019 16:24 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionRestricted Stock Units · Derivative	1,409	$0.00	$0.00	Disclosure SEC source: 0001179110-19-001700 · edgar.xml · derivative · entry 3 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,276 Underlying: Common Stock · 1,409 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017. F4 · derivative.exercise_date: Subject to certain criteria, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F4 · derivative.expiration_date: Subject to certain criteria, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document
February 07, 2019 Filed Feb 11, 2019 16:24 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	1,409	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-19-001700 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document
November 20, 2018 Filed Nov 21, 2018 16:24 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	535	$12.30	$6,580.50	Disclosure SEC source: 0001179110-18-013085 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,041 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
November 12, 2018 Filed Nov 14, 2018 16:31 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	530	$13.15	$6,969.50	Disclosure SEC source: 0001179110-18-012844 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,576 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.